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Obesity has been implicated as a risk factor for insulin resistance and cardiovascular 
diseases (CVDs). Although the association between obesity and CVD is a well-established 
phenomenon, the precise mechanisms remain incompletely understood. This has led to 
a relative paucity of therapeutic measures for the prevention and treatment of CVD and 
associated metabolic disorders. Recent studies have shed light on the pivotal role of 
prolonged endoplasmic reticulum stress (ERS)-initiated activation of the unfolded protein 
response (UPR), the ensuing chronic low-grade inflammation, and altered insulin signaling 
in promoting obesity-compromised cardiovascular system (CVS). In this aspect, potential 
ways of attenuating ERS-initiated UPR signaling seem a promising avenue for therapeutic 
interventions. We review intersecting role of obesity-induced ERS, chronic inflammation, 
insulin resistance, and oxidative stress in the discovery of targeted therapy. Moreover, this 
review highlights the current progress and strategies on therapeutics being explored in 
preclinical and clinical research to modulate ERS and UPR signaling.
Keywords: obesity, cardiac dysfunction, endoplasmic reticulum stress, unfolded protein response, inflammation, 
insulin resistance, oxidative stress
INTRODUCTION
Obesity is a major health problem worldwide and often associated with an increased prevalence 
of cardiovascular diseases (CVDs) and premature death. According to the World Health 
Organization (WHO), there were over 1.9 billion overweight adults in 2016, of whom 650 million 
were obese (WHO, 2018). There are also 2.6 million estimated annual deaths associated with 
obesity-related diseases.
ERS Activates UPR SignalingAmen et al.
2 September 2019 | Volume 10 | Article 977Frontiers in Pharmacology | www.frontiersin.org
An increase in the prevalence of obesity entails an increase 
in confounding cardiometabolic disorders. Some of these 
obesity-linked cardiometabolic health problems include CVD, 
type 2 diabetes mellitus (T2DM), hypertension, myocardial 
infarction, atherosclerosis, and stroke (Poirier et al., 2006). 
According to WHO (2017), an estimated 17.7 million people 
died from CVD in 2015, of which 13% were because of coronary 
heart disease. Epigenetics and traditional risk factors such as 
hypercholesterolemia, hyperlipidemia, T2DM, and hypertension 
are significant contributors to the increasing prevalence of CVD. 
However, obesity is considered an independent factor for the 
increased prevalence of different subtypes of CVD including 
hypertension, stroke, coronary heart disease (CHD), heart 
failure (HF), and atrial fibrillation (AF) (Lavie et al., 2014; 
Ndumele et al., 2016).
Currently, various preventive public health strategies 
ranging from managing the risk factors, lifestyle change, 
physical exercise, and smoking cessation aimed at reducing 
the incidence of CVD are in implementation (Tomé-Carneiro 
and Visioli, 2016). Several pharmacological drugs, such as 
propranolol, digoxin, hydrochlorothiazide, procainamide, 
atorvastatin, lovastatin, rosuvastatin, simvastatin, beta-blockers, 
and angiotensin-converting enzyme (ACE) inhibitors are also 
in use for management of CVDs (Opie, 2000). Although the 
number of therapeutic agents used for the management of 
cardiovascular pathologies has increased steadily, there is 
also growing concern over serious and frequent adverse drug 
reactions induced by commonly used cardiovascular drugs. 
The most common drug effects induced by cardiovascular 
drugs are toxicity, anorexia, nausea, vomiting, bradycardia, 
headache, weakness, hypokalemia, and hyperuricemia (Tomé-
Carneiro and Visioli, 2016). According to an observational, 
prospective, case–series study conducted in Iran, the rate of 
adverse drug reactions induced by cardiovascular drugs was 
24.2%. The most frequently vulnerable sites for cardiovascular 
drug adverse effects were the central/peripheral nervous 
systems and the gastrointestinal systems, accounting for 23.5% 
and 16.5%, respectively (Mohebbi et al., 2010). In addition, 
some of these drugs were reported with pharmacokinetic 
or pharmacodynamic interactions, most prevalently on the 
muscular system, hepatic function, and renal function, leading 
to interference with the metabolism or hemodynamic of another 
drug, which is used as co-treatment (Opie, 2000; Anderson 
and Nawarskas, 2001). Entirely, this has resulted in apparent 
limitations in effective therapeutics for CVD. Therefore, the 
search for better treatment strategies and options to overcome 
these challenges remains a priority.
Knowledge of underlying mechanisms interrelating 
obesity and cardiac dysfunction is essential to identify 
potential therapeutic targets for cardiovascular dysfunctions. 
In the last few decades, significant effort has been made to 
elucidate the association between obesity and CVD. However, 
the biomolecular events and mechanisms governing the 
development of obesity-related CVD remain unclear. This 
has led to a relative paucity of therapeutic measures for 
the prevention and treatment of obesity-related CVD and 
associated metabolic disorders.
Interestingly, numerous in vitro and animal studies have 
documented the role of endoplasmic reticulum stress (ERS) in 
the pathophysiology of different subtypes of CVD. Recent studies 
have highlighted the pivotal role of prolonged ERS-initiated 
activation of the unfolded protein response (UPR), the ensuing 
chronic low-grade inflammation, and altered insulin signaling 
in promoting obesity-compromised cardiovascular system 
(CVS) (Hotamisligil, 2010; Thorp, 2012; Liu and Dudley, 2014; 
Szymański et al., 2017; Zhang et al., 2017b). However, the precise 
mechanism of these phenomena is not clearly understood. 
Therefore, a thorough understanding of how obesity causes 
persistent ERS in the myocardium and triggers provocative 
activation of the UPR signaling, inflammation, and insulin 
resistance is critical.
In the current article, we review the existing knowledge of 
obesity-linked CVD, ERS, inflammation, insulin resistance, and 
oxidative stress in the pathophysiology of obese compromised 
CVS. Moreover, we summarize molecular mechanisms of 
ERS-associated CVDs, highlighting common interplaying 
mechanisms that could be of tendency for future novel drug 
discovery. Furthermore, our review will discuss current progress 
in CVD therapeutics and the roles of phytochemicals and small 
molecules as potential therapeutics for the prevention and 
treatment of CVDs, emphasizing new directions for studying 
the pathophysiology of CVDs and for developing novel drugs 
targeting ERS and UPR.
Abbreviations: ACE, acetylcholine enzyme; ATF4, activating transcription factor 
4; ATF6, activating transcription factor 6; ATP, adenosine triphosphate; APN, 
adiponectin; ATMs, adipose tissue macrophages; ARE, antioxidant response 
element; BiP, binding immunoglobulin protein; CVD, cardiovascular dysfunction; 
CVS, cardiovascular system; CHOP, C homologous protein; c-JNK, C-Jun 
N-terminal kinase; CD36, a cluster of differentiation 36; CAD, coronary artery 
disease; CRP, C-reactive protein; COX-2, cyclooxygenase-2; DAMPs, danger-
associated molecular patterns; DNA, deoxyribonucleic acid; DCM, diabetic 
cardiomyopathy; DAGs, diacylglycerols; ER, endoplasmic reticulum; ERAD, 
endoplasmic reticulum-associated degradation; ERS, endoplasmic reticulum 
stress; ERSE, endoplasmic reticulum stress response element; eNOS, endothelial 
nitric oxide synthase; FAT, fatty acid translocase; ECG, echocardiography; ERK, 
an extracellular signal-regulated kinase; FGF, fibroblast growth factor; FFA, free 
fatty acids; GRP78, glucose-regulated protein 78; GRP94, glucose-regulated 
protein 94; GLUT1, glucose transporter 1; GLUT4, glucose transporter 4; GPx, 
glutathione peroxidase; GADD34, growth arrest and DNA-damage-inducible 
protein 34; HbA1c, glycosylated hemoglobin; HO-1, heme oxygenase-1; H2O2, 
hydrogen peroxide; HO, hydroxyl radicals; eIF2a, initiation factor 2a; IRE1, 
inositol-requiring enzyme 1; IRS-1, insulin receptor substrate 1; IRS-2, insulin 
receptor substrate 2; IL-6, interleukin-6; IMT, intima-media thickness; ICAM-
1, intracellular adhesion molecule 1; LPS, left ventricular dysfunction; LVD, 
lipopolysaccharide; LDL, low-density lipoprotein; LO, lypoxidases; NOX, 
mitochondrial NADPH oxidases; MPO, myeloperoxidases; NO, nitric oxide; 
ATF6N, N-terminus of ATF6a; Nrf2, nuclear E2-related factor-2; NF-κB, 
nuclear factor-kappa B; NOD, nucleotide oligomerization domain; OxPL, 
oxidized phospholipids; PAMPs, pathogen-associated molecular patterns; PRRs, 
pattern-recognition receptors; OONO−, peroxynitrite; PERK, PKR-like ER 
kinase; PDI, protein disulfide isomerase; ROS, reactive oxygen species; RAGE, 
receptor for advanced glycation end-products; O2, singlet oxygen; S1Ps, site one 
proteases; S2Ps, site two proteases; sXBP1, spliced X-box binding protein 1; SAT, 
subcutaneous adipose tissue; −O2, superoxide; SOD, superoxide dismutase; TAGs, 
triacylglycerides; TLRs, Toll-like receptors; TNF-α, tumor necrosis factor-α; 
TRAF2, tumor necrosis factor-α receptor-associated factor 2; T2DM, type-2 
diabetes mellitus; VCAM-1, vascular cell adhesion molecule 1; LVH, ventricular 
hypertrophy; VLDL, very-low-density lipoprotein; VAT, visceral adipose tissue; 
WHO, World Health Organization; XO, xanthine oxidases.
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CORRELATION BETWEEN OBESITY 
AND CARDIAC DYSFUNCTION
Obesity is a nutritional disorder that results from an accumulation 
of body fat in certain parts of the body in a way that adversely 
affects health. It often occurs due to an imbalance between 
dietary intake and energy expenditure. The association between 
obesity and CVD is a well-established phenomenon. Data from 
experimental, epidemiological, and clinical studies, including the 
Framingham Heart Study, the Manitoba Study, and the Harvard 
Public Health Nurses Study (Poirier et al., 2006; Van Gaal 
et al., 2006), support the notion that obesity is an independent 
risk factor and leads to adverse cardiometabolic effects. Of 
significant note, in the Framingham Heart Study involving the 
echocardiography (ECG) of healthy and obese individuals, the 
latter had increased left ventricular hypertrophy (Siti et al., 
2015). Moreover, several experimental and clinical studies have 
shown the role of excess calories, an underlying problem leading 
to obesity, in the development of obesity-associated CVD, 
including cardiac hypertrophy and myocardial dysfunction 
(Guo et al., 2013). The correlation between excess nutrition/
overweight/obesity and other risk factors such as hyperlipidemia, 
high free fatty acids (FFAs), reactive oxygen species (ROS), ERS, 
inflammation, and insulin resistance and cardiac dysfunction is 
illustrated in the schematic diagram in Supplemental Material.
ROLE OF ENDOPLASMIC RETICULUM 
STRESS (ERS) IN CVD
Endoplasmic Reticulum (ER)
ER was first discovered by Porter et al. (1945) in cultured 
mice fibroblast, and it is an organelle found in all eukaryotic 
mammalian cells except matured red blood cells. ER is one of 
the vital cell organelles and a primary site for the biosynthesis 
of nearly 33% to 35% of all cellular proteins (Glembotski, 2008; 
Minamino and Kitakaze, 2010). ER is a cellular compartment 
responsible for several homeostatic responses including synthesis 
and post-translational modifications of secretory, luminal, and 
transmembrane proteins and folding and maturation of newly 
synthesized secretory and membrane proteins (Malhotra and 
Kaufman, 2011). In addition, ER serves as a site for steroid 
hormone synthesis, glucose concentration regulation, calcium 
homeostasis, and lipid metabolism (Liu et al., 2015).
The ER has two membrane subdomains, namely, rough and 
smooth ER. While the laminar structured rough ER is mainly 
responsible for synthesis, modification, folding, and processing 
of nascent polypeptide chains of secreted, transmembrane, and 
luminal proteins and Ca2+ signaling, the tubular structured, 
smooth ER is a central site for lipid biosynthesis and modification 
as well as Ca2+ signaling (Luchetti et al., 2017).
In eukaryotic cells, newly synthesized proteins need to 
undergo post-translational modification and proper folding 
in the ER lumen, as only correctly folded proteins are routed 
to the nucleus, Golgi apparatus, and cytosol. Protein folding is 
the process by which a linear polymer of amino acids acquires 
a unique 3D structure (the native conformation) capable of 
performing its cellular function. During the folding process, 
proteins often interact with molecular chaperones that bind to the 
hydrophobic regions of unfolded proteins to facilitate the folding 
process (Kitakaze and Tsukamoto, 2010). The post-translational 
modification processes include folding of the proteins into naïve 
3D conformation, glycosylation, and disulfide bond formation 
(Chen et al., 2015). These complex cellular processes are governed 
by a highly regulated quality control system within the ER known 
as the UPR (Gardner et al., 2013), which is initiated in response 
to homeostatic de-arrangements, which trigger endoplasmic 
reticulum stress (ERS).
ERS is cellular stress within the ER, which was first described 
by Kozutsumi in 1998, when increased production of the 70-kDa 
glucose-regulated protein (GRP78) was induced in the presence 
of misfolded foreign proteins in the cytoplasm (Kozutsumi 
et al., 1988). Cells are susceptible to a range of environmental 
stimuli including radiation, hypoxia shock, heat, and oxidation, 
nutrient deprivation, energy disturbance, calcium depletion, 
oxidative stress (Kitakaze and Tsukamoto, 2010; Toko et al., 
2010), and epigenetic alterations such as altered glycosylation, 
deoxyribonucleic acid (DNA) damage, DNA methylation, and 
histone modification (Schiano et al., 2015), which can result in 
aberrant protein folding and triggers ERS.
ERS and the UPR Signaling
The UPR is a highly conserved adaptive system found in 
most eukaryotes and yeast. The UPR is a component of the 
ER adaptive system that comprises three principal signaling 
pathways, namely, inositol-requiring enzyme 1 (IRE1), PKR-like 
ER kinase (PERK), and activating transcription factor 6 (ATF6). 
These UPR sensors have two terminals, N-terminus located 
inside the lumen and C-terminus located in the cytosol, forming 
a bridge connecting the ER lumen to the cytosol (Minamino 
and Kitakaze, 2010). In addition, the UPR adaptive system 
is mediated by molecular chaperones and luminal enzymes, 
including the binding immunoglobulin protein (BiP) such as 
GRP78 and GRP94, calreticulin, and lectin calnexin, including 
protein disulfide isomerase (PDI) and Erp57, thiol-disulfide 
oxidoreductase (Malhotra and Kaufman, 2011). BiP/GRP78 is an 
Hsp70 family ER-resident molecular chaperone comprising an 
N-terminal ATPase and a C-terminal protein-binding domain 
and plays a mediating role in correct secretory and membrane 
protein folding, maintaining ER membrane permeability, 
and plays a critical role as a master regulator of ERS signaling 
(Wolfson et al., 2008).
In mammalian cells, protein synthesis is highly regulated to 
the changes induced by various environmental or pathological 
stimuli (Shi et al., 1998). Accumulation of misfolded proteins in 
the cytosol triggers a heat-shock response, which stimulates the 
transcription of genes encoding cytosolic chaperones to refold 
destabilized proteins. At the same time, accumulation of misfolded 
proteins in the ER initiates a signaling cascade extending from the 
ER to the nucleus that induces a comprehensive gene expression 
program to increase the protein folding capacity of the cell 
according to the physiologic demands (Kitakaze and Tsukamoto, 
2010). Likewise, disturbance in a physiologic function of the ER 
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leads to ERS and triggers activation of the evolutionarily conserved 
UPR to compensate for the damage. Furthermore, downstream of 
the three UPR signaling pathways, transcription factors are also 
activated, and UPR associated genes are upregulated. Eventually, 
activated UPR signaling mitigates ERS by suppressing synthesis 
of global proteins, inducing ER-associated degradation (ERAD) 
of unfolded/misfolded protein, and enhancing production of 
molecular chaperones, which facilitate proper protein folding 
(Gardner and Walter, 2011). However, persistent perturbation 
of the ER leads to malfunction within the network and chronic 
failure of the UPR adaptive system.
When the ERS in the lumen is within the handling capacity 
of the UPR adaptive mechanism, the three branches of the UPR 
adaptive system (IRE1, PERK, and ATF6) are activated, leading 
to attenuation of global protein translation, synthesis of folding 
enzymes, and ERAD; and as a result, stress is resolved (Gardner 
and Walter, 2011). While synthesis of folding enzymes facilitates 
proper protein folding activity, attenuation of the global protein 
translation reduces the folding burden. Similarly, the ERAD 
eliminates aggregates of misfolded proteins, and this reduces 
the unfolded protein load within the network. As a result, the 
alterations caused by the ER are corrected and replenished without 
any further prolonged effects. However, chronic accumulation of 
unfolded/misfolded proteins followed by persistent disruption of 
the ER lumen may lead to malfunction of the UPR signaling to 
adapt itself to the changes caused by unfolded protein aggregates 
(Toko et al., 2010; Gardner et al., 2013). Consequently, this leads 
to latent apoptotic or necrotic cell death (Xu et al., 2005; Boyce 
and Yuan, 2006). Many lines of evidence have reported the role 
of ERS and initiation of UPR, which in chronic stress may lead to 
myocardial apoptosis, in the pathophysiology of various CVDs 
including heart failure, atherosclerosis, cardiac hypertrophy, 
and ischemic heart disease (Minamino and Kitakaze, 2010). 
Interestingly, the secreted and transmembrane proteins in the 
ER play important roles in maintaining myocardial health 
and disease (Doroudgar and Glembotski, 2012). In addition, 
some cardiac pathologies are implicated to impair secreted and 
membrane protein folding and disturb the homeostatic balance. 
For example, ERS-initiated apoptotic cell death was reported to 
play a favorable role in the pathophysiology of several chronic 
diseases including CVD and T2DM (Tabas and Ron, 2011). The 
adaptive and maladaptive mechanism mediated by the UPR 
signaling pathway is illustrated in Figure 1.
The Three Branches of UPR Signaling Effectors
The three main proximal effectors of UPR (PERK, IRE1, and 
ATF6) are activated with different strengths and at different 
time courses (Glembotski, 2014) and may act deferentially or 
synergistically. These effectors can serve both adaptive and 
maladaptive roles in many of the cell types. Under normal 
FIGURE 1 | Adaptive and maladaptive mechanisms of UPR signaling. Following the onset of ERS in the cardiac system, cardiac-specific UPR is activated, and 
the three branches of signaling transducers (PERK, IRE1, and ATF6) are activated. Furthermore, downstream of the three UPR signaling pathways, transcription 
factors are also activated, and unfolded protein response (UPR) associated genes are upregulated. In general, activation of the UPR signaling networks initiates 
attenuation of the global protein translation, synthesis of folding chaperones and enzymes, and ERAD of misfolded/unfolded proteins in the ER lumen. Thus, through 
coordinated attenuation of global protein synthesis, upregulation of ER-resident chaperones, and activation of ERAD, the UPR often manages to resolve/restore 
acute homeostasis imbalances caused by various stimuli; thus, the cells survive (adaptive mechanism). The primary goal of the UPR activation is to avoid damages 
caused by the ERS through its adaptive functional role, which reestablishes the ER homeostasis, enhancing cell survival. However, intense ERS makes the cells 
succumb to apoptosis death (maladaptive mechanism). Once the ERS turns out to be persistent, transcription factors including CHOP, JNK, and caspases are 
activated, and members of the Bcl family such as Bcl-2 are suppressed, thereby eliciting programmed cell death. 
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circumstances, all of these sensors exist in an inactive state 
through their maintained interaction with GRP78 via their 
luminal N-terminus (Oikawa et al., 2009). There is a consensus 
among the scientific community that the three UPR signaling 
pathway receptors are initiated in response to ERS, which can 
be triggered by various degrees of stimuli. The three arms of 
UPR transduction signaling networks detect the stress in the ER 
with their luminal domain and use their cytoplasmic domain to 
interact and communicate with transcriptional or translational 
machinery (Ron and Walter, 2007). Nevertheless, the exact 
mechanism how the three arms of ERS sensors detect and 
recognize the ER environment remains a subject of scientific 
debate. In the past, three mechanisms have been postulated to 
explain these phenomena, namely, the direct, semi-direct, and 
indirect (Kimata and Kohno, 2011; Parmar and Schröder, 2012). 
According to the indirect or negative regulation of ERS sensors, 
in unstressed cells, all the three ERS receptors are maintained 
inactive through their association with the ER chaperone BiP/
GRP78. However, accumulated unfolded proteins in the ER lead 
to dissociation of GRP78 from the three ERS receptors, leading 
to subsequent activation of the three ERS sensors (Liu et al., 2000; 
Oikawa et al., 2009; Senkal et al., 2010). Contrary to this concept, 
it was reported that in yeast, the luminal domain of IRE1 detects 
accumulation of unfolded proteins through dissociation of BiP/
GRP78 and direct interaction of IRE-1 receptor with unfolded 
proteins in the ER lumen (Kimata and Kohno, 2011; Parmar and 
Schröder, 2012). However, studies have revealed that unlike yeast 
IRE-1, the regulation of IRE-1 in mammals is dependent on the 
dissociation of BiP (Liu et al., 2000; Oikawa et al., 2009), implying 
that self-activation of IRE-1 may not be ligand dependent. In this 
regard, for the purpose and scope of this review, we are entirely 
confined to the indirect or negative regulation mechanism of the 
ERS sensors by the BiP/GRP78 chaperone proteins without any 
conflict with the rest of the proposed mechanisms.
PERK Signaling Pathway
PERK is one of the three main UPR signaling arms that are 
responsible for transducing ERS. First identified as a serine/
threonine kinase in pancreatic islets of rat (Shi et al., 1998), 
PERK is a type I ER-resident transmembrane protein that 
mediates signal transduction during ERS (Harding et al., 
1999). PERK is primarily involved in eukaryotic translation 
initiation factor 2 (eIF2α)-mediated translational attenuation 
and suppression of protein synthesis in the ER compartment 
(Sano and Reed, 2013). Under ERS, PERK dissociates 
from BiP/GRP78 and undergoes oligomerization and 
autophosphorylation, which leads to phosphorylation of the 
eukaryotic initiation factor eIF2α, a major substrate for PERK 
kinase activity (Kondratyev et al., 2007; Wolfson et al., 2008). 
Ultimately, this downstream signaling results in attenuation 
of global protein synthesis and translational activation of 
transcription factors (Shi et al., 1998) including ATF4 and C 
homologous protein (CHOP), which promote transcription of 
cell survival genes (Lei et al., 2017; Lumley et al., 2017). The 
translational arrest reduces the protein synthesis load, thereby 
maintaining the ER to its cellular homeostasis and facilitating 
efficient ER protein folding and assembly.
The role of PERK not is limited to the activation of eIF2α/
ATF4-mediated attenuation of global protein synthesis, 
translational activation of transcription factors, and apoptotic 
event via CHOP but also encompasses ROS detection and ER and 
mitochondrial tethering (Thoudam et al., 2016). Following eIF2α 
phosphorylation, the mRNA that encodes ATF4 is translated 
more efficiently and leads to increased expression of ATF4 
(Glembotski, 2008). As a result, ATF4 is translocated into the 
nucleus where it binds to the unfolded protein response element 
(UPRE), resulting in transcriptional modification of UPR target 
genes including the proapoptotic transcription factor, CHOP 
(Lei et al., 2017). It is noteworthy that the ATF4 transcriptional 
activity in the early stage of ERS induces prosurvival pathways, 
whereas in the late phase where ERS is prolonged, it initiates 
the proapoptotic transcriptional programs through increased 
expression of the proapoptotic protein CHOP (Groenendyk et al., 
2010). On the other hand, phosphorylation of PERK pathways 
(eIF2α/ATF4/CHOP) attenuates global translational process 
and inhibits transcription of I kappa B alpha (IκBα), leading to 
hyperactivation of nuclear factor-kappa B (NF-κB) (Liu et al., 
2015). However, if the ERS is restored, activation of GADD34 
(growth arrest and DNA-damage-inducible protein 34) follows, 
and this dephosphorylates eIF2α via negative feedback (Basseri 
and Austin, 2012), resulting in attenuation of translational 
repression exerted due to ERS (Figure 2).
The IRE-1 Signaling Pathway
IRE-1 is also a transmembrane protein conserved in all 
eukaryotic cells and plays significant roles in the UPR adaptive 
system. The IRE-1 is a transmembrane protein that encodes a 
type 1 ER-resident transmembrane protein and is present as an 
inactive monomer until it undergoes autophosphorylation and 
becomes an active oligomer forming clusters on the ER (Li et al., 
2010). IRE1 has protein kinase and ribonuclease domains that 
extend through its cytoplasmic region. Under normal conditions, 
the IRE-1 remains bound to GRP78 in the ER membrane, 
forming an inactive complex. However, in response to ERS and 
dissociation of GRP78 from the ER lumen, IRE-1 undergoes 
homodimerization and autophosphorylation and is released as 
an active RNase of IRE-1 with conformational change (Liu et al., 
2000; Oikawa et al., 2009). Upon autophosphorylation, unlike 
the PERK receptor, IRE-1 exhibits a novel endoribonuclease 
activity (Harding et al., 1999; Glembotski, 2008), which leads to 
excision and splicing of its substrate, the 26-nucleotide sequence 
XBP1 mRNA (Yoshida et al., 2001). The splicing of XBP1 mRNA, 
which takes place in the cytosol, generates a transcript with a 
new open reading frame that encodes the expression of an active 
form of XBP1 (Yoshida et al., 2001). This results in spliced XBP1 
protein (sXBP1) with 5′ and 3′ mRNA fragments that enhance 
internal ribosome entry site (IRES)-dependent translation of 
XBP1 mRNA and leads to transactivation of UPR target proteins 
including CHOP, XBP1, endoplasmic reticulum oxidoreductin 1 
(ERO1), P58IPK, ER degradation-enhancing α-mannosidase-
like protein (EDEM), and RAMP-4 (Toth et al., 2007).
The XBP1 mRNA expression is dependent on the activation 
of the ATF6 receptor protein. Translocation of the spliced XBP1 
mRNA into the nucleus facilitates the upregulation of genes that 
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are crucial for protein folding and secretion, and ERAD (Basseri 
and Austin, 2012; Thorp, 2012). The translocated sXBP1 mRNA 
binds to the promoter region of the ERS response element 
(ERSE) I and II (ERSE-I: CCAAT(N9) CCACG; ERSE-II: 
ATTGG(N1) CCACG) and the mammalian UPR element 
(mUPRE: TGACGTGG/A) to regulate a variety of UPR-related 
genes that are essential to induce degradation of malfunctioned 
cells (Minamino and Kitakaze, 2010; Luchetti et al., 2017). On the 
other hand, IRE-1 collaborates with TRAF2 to activate protein 
kinases that are associated with inflammatory response and 
cellular apoptosis, particularly the apoptosis signal-regulating 
kinase 1 (ASK1), which leads to activation of JNK (Kim et al., 
2008) (Figure 2).
ATF6 Signaling Pathway
ATF6 is an ERS-regulated transmembrane transcription factor 
with an N-terminal domain in the cytosol and a C-terminal 
in the ER lumen (Zhang and Kaufman, 2004), which activates 
the transcription of ER molecular chaperones to sense ERS. 
In addition to the two isoforms, ATF6α and ATF6β, there 
are other ATF6-related membrane proteins, namely, Oasis, 
Luman, CREB4, CREB-H, and BBF2H7, all of which are ER 
transmembrane proteins that are cleaved and translocated to the 
nucleus under ERS (Glembotski, 2008). Although ATF6 does 
not undergo oligomerization or autophosphorylation (Zhang 
and Wang, 2012), the activation mechanism is partially similar 
to that of PERK and IRE-1, which is through dissociation of BiP/
GRP78. In an experiment, (Shen) described the dissociation of 
BiP/GRP78 during ERS, which allows ATF6 to be relocated to 
the Golgi complex, as follows. Under ERS conditions, GRP78 
dissociates from the N-terminus of ATF6, and this initiates the 
translocation of ATF6 from the ER lumen to the Golgi complex 
(Shen et al., 2002), suggesting that BiP/GRP78 dissociation 
from ATF6 in response to ER stress is detrimental for the 
downstream activation of ATF6-mediated signaling pathway. 
Translocated to the Golgi, ATF6 is spliced and proteolyzed by 
the Golgi resident site 1 protease (S1P) and site 2 protease (Ye 
et al., 2000). The fact that the proteases (SP1 and SP2), which 
FIGURE 2 | A schematic representation of downstream effectors, target genes, and possible outcome in the ERS-activated UPR. Under ERS, dissociation of 
GRP78 from its luminal domain leads to oligomerization and autophosphorylation of PERK, ensuing its kinase and endoribonuclease activities. As a result, the α 
subunit of eukaryotic initiation factor 2 (eIF2) undergoes phosphorylation, resulting in translational attenuation characterized by a reduction in protein biosynthesis. 
Parallelly, this downstream phosphorylation of eIF2 leads to increased expression of ATF4 and translocation into the nucleus where it binds to the UPR element 
(UPRE) resulting in transcriptional modification of UPR target genes including the proapoptotic transcription factor, C homologous protein (CHOP), GRP78, 
GRP94, and GADD34, while attenuating global translational process, but PERK phosphorylation also inhibits transcription of I kappa B alpha (IκBα), leading to 
hyperactivation of NF-κB and increased production of inflammatory cytokines (Figure 4). On the other hand, ERS leads to autophosphorylation of IRE-1, leading 
to excision and splicing of its substrate, XBP1 mRNA. Consequently, this results in spliced XBP1 protein (sXBP1), which translocates into the nucleus, and this will 
upregulate genes for protein folding enzymes secretion and ER-associated protein degradation (ERAD). Noteworthy, the ATF6 is activated following PERK and prior 
to IRE1. The GRP78 dissociates from ATF6 and recruited to luminal protein aggregates resulting in translocation of ATF6’s cytosolic fraction to the Golgi, where it is 
spliced and proteolyzed by site one proteases (S1Ps) and site two proteases (S2Ps). Eventually, this leads to the release of the cytosolic domain of ATF6 and entry 
into the nucleus where it sequesters with the ERS response element (ERSE) resulting in the activation of UPR target genes including XBP1, CHOP, and GRP78/
BiP, GRP94, PDI. However, chronic ERS, which may result from persistent perturbation of the ER, can lead to malfunction within the network and failure of the UPR 
adaptive system. And as a result, the PERK-mediated post-translational attenuation is inhibited and further accumulations of unfolded protein aggregates, leading to 
initiation of C homologous protein (CHOP)-mediated apoptotic deaths of the cells.
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catalyze the cleavage of ATF6, are located in the Golgi suggests 
that ATF6 translocation to Golgi is critical for its activation 
(Morishima, 2011). Consequently, the cleavage of ATF6 at a 
juxta-membrane site leads to its release into the cytosol (Xu et 
al., 2005). The cytosolic 50-kDa soluble fragment of ATF6 is 
then translocated into the nucleus where it sequesters to ATF/
cAMP response elements (CRE) and endoplasmic reticulum 
stress response element (ERSE-I) (Sano and Reed, 2013). In 
turn, this leads to transcriptional regulation and activation of 
UPR target genes including XBP1, CHOP, and GRP78/BiP 
(Basseri and Austin, 2012; Thorp, 2012).
ATF6 is a major inducer of the expression of genes encoding 
molecular chaperone and elements of ERAD (Adachi et al., 
2008). In the heart, there are two ATF6-inducible genes, namely, 
RCAN1 and Derl3, which are shown to be adaptive and encode 
proteins that attenuate increased protein-folding demand and 
facilitate degradation of unfolded proteins (Glembotski, 2014). 
According to a study by Toko, Takahashi, et al. data from in vivo 
experimental study conducted using mice indicated that ATF6 
activity was increased in a mouse model of myocardial infarction. 
Furthermore, treatment of myocardial infarction-induced mouse 
with ATF6 inhibitor, 4-(2-aminoethyl)benzenesulfonyl fluoride, 
further reduced cardiac dysfunction and increased mortality 
rate. However, suppression of ATF6 with pharmacological 
agent  improved the cardiac function, suggesting the critical 
role  of ATF6 in both pathological and physiological states 
(Toko et al., 2010).
In response to ERS, all the three UPR receptors, PERK, IRE1, 
and ATF6, are activated to mediate adaptive and/or maladaptive 
functions. Although ATF6 is believed to predominantly play an 
adaptive role in many of the cell types, studies showing the role of 
ATF6 in the maladaptive UPR signaling pathway via activation 
of the apoptotic mechanism are emerging. For example, a 
study conducted on myoblast revealed the activation of ATF6 
in apoptotic myoblasts during differentiation, suggesting the 
maladaptive function of ATF6 (Morishima, 2011). Although 
much details remain, the finding of this and other relevant 
studies has highlighted that ATF6 may trigger apoptosis during 
persistent ER stress via activation of downstream distal effectors 
including CHOP, JNK, and the proapoptotic Bcl-2 family proteins 
(Senkal et al., 2010) (Figure 2).
Importantly, the ER and ERS-initiated UPR signaling 
pathway have emerged as critical aspects of diverse physiological 
and pathological processes in many cell types. Perturbations 
caused by protracted stress, abnormal protein synthesis, and 
hypercholesterolemia may disrupt the protein folding capacity 
of ER lumen, leading to accumulation of unfolded/misfolded 
proteins, which eventually causes deleterious effects, designated 
as ERS, on the physiologic function of the cells (Zhang and 
Kaufman, 2004). As a first line of defense, ERS-initiated 
activation of UPR signaling transduction elicits protection 
against moderate ERS through coordinated function of the three 
proximal arms of UPR and ultimately regulate the translation 
and transcription of various proteins and enhance the expression 
of genes encoding molecular chaperones and folding enzymes 
by enhancing ER folding capacity and/or by attenuating protein 
translation. However, in conditions of persistent stress, the UPR 
signaling initiates programmed cell death/apoptosis mechanism 
to eliminate unhealthy cells and to suppress the spread of their 
toxic effects (Figure 2).
ERS and Inflammation in CVD
Inflammation
The ability of eukaryotic organisms to survive is dependent 
on their ability to fight and defend themselves from infectious 
organisms, heal damage or injury caused, and reserve energy 
for times of high demand. Inflammatory responses triggered by 
the collaborated activity of the innate and adaptive immunity 
are among such natural defensive systems through which 
multicellular organisms overcome infectious agents or deviant 
environmental stimuli. Metabolic and immune systems are 
among the homeostatic components that have evolved to be 
closely linked and codependent (Wellen and Hotamisligil, 2005). 
Thus, the integration of metabolism and immunity determines 
the maintenance of a complete immune system and good health. 
However, under aberrant conditions, for example, in nutritional 
excess or poor nutrition, this integration can trigger deleterious 
health effects.
Inflammation is an adaptive mechanism initiated in response 
to cell damage caused by endogenous or exogenous stimuli 
such as infectious microorganisms, trauma, or chemical agents 
(Kawasaki et al., 2012). In the normal physiological state, acute 
inflammation acts as an adaptive system to get rid of a stimulus. 
However, chronic inflammation resulting from repeated injury 
and repair leads to damage and malfunctions to the tissue. 
Inflammation is considered a crucial element in the development 
and progression of chronic metabolic diseases including diabetes 
and CVD (Thoudam et al., 2016). Chronic inflammation of the 
vascular system is implicated in the pathophysiology of cardiac 
dysfunction. CVD is a chronic inflammation of the lining of the 
blood vessel, which results due to transendothelial infiltration 
of cholesterol-rich and atherogenic Apo-B lipoproteins from 
the plasma into the intima. Consequently, these infiltrated 
lipoproteins are retained in the sub-endothelia, facilitating 
macrophage and T-cell migration and sequestering with one 
another and cells of the arterial wall, an event that promotes 
atherosclerosis (Nakayama and Wang, 2010).
Unlike the classical inflammation with typical cardinal 
features such as pain, heat, swelling, and redness, chronic low-
grade inflammation, also known as metabolic inflammation, is a 
form of inflammation often triggered by adiposity/obesity (van 
Diepen et al., 2013). This type of inflammation is associated 
with the development of metabolic syndrome including 
atherosclerosis, hypertension, and prothrombin (Emanuela 
et al., 2012), which are risk factors for the development of 
T2DM and CVD. Although the mechanism of chronic low-
grade inflammation is not precisely known, the increased 
translocation of lipopolysaccharide (LPS) or endotoxin from 
gut to circulation, which causes metabolic endotoxemia, 
is speculated. In addition, animal studies have shown that 
diets high in saturated fatty acids and cholesterol activate 
inflammatory processes in adipose tissue, liver, and vasculature 
(van Diepen et al., 2013).
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Several studies have documented a strong association 
between obesity and chronic inflammation. Chronic low-grade 
systemic and local inflammation that is triggered in condition 
of nutritional excess is implicated in various metabolic disorders 
including T2DM and CVD. Obesity itself is characterized 
by an inflammatory response in which crucial mediators of 
inflammation like tumor necrosis factor-alpha (TNF-α) show 
significant patterns of expression in both animal models and 
humans. In addition, data obtained from transcriptional profiling 
studies showed that inflammatory and stress-response genes are 
highly upregulated in adipose tissue of obese animals (Wellen 
and Hotamisligil, 2005).
Continuous deposition of lipids and expansion or 
hypertrophy of adipose tissue (AT) stimulates adipose tissue 
macrophages (ATM) and other infiltrating macrophages to 
generate excess inflammatory cytokines including interleukin-6 
(IL-6), TNF-α, c-Jun N-terminal kinase (c-JNK), and NF-κB, 
resulting in metabolic inflammation (van Diepen et al., 2013; 
Chen et al., 2015). In addition, the presence of excess ROS 
can also trigger oxidation of low-density lipoprotein (LDL), 
which is taken up by macrophages via scavenger receptors, 
leading to the development of atherogenesis (Sozen and Ozer, 
2017), a common feature of CVD. These events are considered 
contributing factors for obesity-associated inflammation in 
which pro-inflammatory cytokines like TNF-α and IL-6 are 
increasingly expressed and anti-inflammatory markers such as 
adiponectin are downregulated.
Pattern-recognition receptors (PRRs) including Toll-like 
receptors (TLRs) and the receptor for advanced glycation end-
products (RAGE) are implicated in the pathophysiology of 
obesity-related inflammation and associated complications. The 
PRRs are components of innate immunity and are activated in 
response to aberrant conditions such as over-nutrition. TLRs 
comprise different subfamilies that have unique features of 
sensing pathogens and detecting tissue injury via the specific 
pathogen-associated molecular patterns (PAMPs) and the 
danger-associated molecular patterns (DAMPs) (Ota, 2014).
ERS-Mediated Inflammation
As discussed in Section 3.2, when ERS is induced, the UPR 
signaling is activated, resulting in increased expression of GRP78 
and phosphorylation of IRE-1, PERK, and ATF6 signaling 
receptors. Through activation of these UPR signaling networks, 
ERS is resolved. However, if the UPR adaptive mechanisms 
fail to restore the imbalance caused by ERS to a physiologic 
homeostasis, the IRE-1α-dependent apoptotic signaling pathway, 
which occurs via diverse pathways, is inevitable. As illustrated in 
Figure 3, phosphorylation of IRE-1α leads to TRAF2 recruitment 
causing activation of downstream signaling of JNK and NF-κB, 
leading to the production of proinflammatory cytokines (Chen 
et al., 2015). Additionally, phosphorylated IRE-1α interacts 
with a mitogen-activated protein kinase (MAPK), ASK1, which 
eventually phosphorylates JNK (Minamino and Kitakaze, 2010).
As discussed in the section PERK Signaling Pathway, PERK 
phosphorylates eIF2α, and downstream signaling of this pathway 
upregulates inflammatory genes and increases secretion of 
proinflammatory proteins including TNF-α and IL-6, resulting 
in persistent inflammation. In parallel, autophosphorylation 
of PERK initiates activation of eukaryotic initiation factor 
2 (eIF2), which further undergoes phosphorylation and 
results in translational attenuation of protein synthesis. This 
downstream phosphorylation of eIF2 leads to increased 
expression of ATF4 and translocation into the nucleus, where 
it binds to the UPRE resulting in transcriptional modification 
of CHOP, a proapoptotic gene transcription factor that initiates 
inflammation as well as apoptosis. IRE-1 recruits TRAF2 and 
causes activation of downstream signaling of kinases including 
JNK and NF-κB, inducing the production of inflammatory 
cytokines. PERK phosphorylates eIF2α, leading to activation 
of NF-κB and CHOP to further promote the expression of 
inflammatory genes (Figure 3).
ERS and activation of the UPR signaling play a crucial role 
in the development of CVDs. For example, UPR activation is 
implicated in ischemic myocardium, cardiac hypertrophy, and 
heart failure. Likewise, increased expression of CHOP and caspase 
12 is implicated in the progression of cardiac hypertrophy to 
heart failure and cardiomyocyte death (Kitakaze and Tsukamoto, 
2010). Many lines of evidence indicated the important role of 
ERS in the development and progression of CVDs, but there 
remains much to understand the molecular mechanisms of 
ERS and chronic activation of UPR signaling pathway in the 
pathogenesis of CVDs. Although most of the knowledgeable 
discussed above are well established in systems other than CVS, 
much remains to learn the CVS-targeted underlying molecular 
mechanisms of ERS-induced CVDs via activation of the UPR 
signaling pathways.
ERS and Insulin Resistance
Insulin Resistance
Insulin, secreted by the pancreatic beta cells, is a key regulatory 
enzyme in carbohydrate–lipid metabolism. Insulin plays a 
significant role in maintaining energy balance in a physiological 
state and helps decrease circulating blood glucose by increasing 
cell permeability to monosaccharides, amino acids, and fatty 
acids. In addition, insulin facilitates metabolic processes such as 
glycolysis, the pentose phosphate cycle, and glycogen synthesis 
in the liver, which eventually leads to reduced circulating blood 
glucose. Metabolic functions of insulin include facilitating 
glucose infusion into metabolic tissues, stimulating the synthesis 
of fatty acids and glycogen, promoting mitochondrial function, 
promoting microcirculation, and cell proliferation (Ye, 2013). 
Insulin also helps downregulate essential gluconeogenic enzymes 
in the liver, promotes triglyceride deposition by accelerating 
glucose degradation via glycolysis and synthesis of free fatty 
acids, and inhibits lipolysis in fat cells (Stafeev et al., 2017).
Activation of the insulin receptor tyrosine kinase, which 
leads to phosphorylation of insulin receptor substrate (IRS) on 
multiple tyrosine residues, is the primary molecular signaling 
node for insulin action (Kahn and Flier, 2000). Insulin binds to 
insulin receptors on the surface of insulin-responsive cells and 
stimulates insulin-responsive receptors and other substrates 
including IRS-1 and IRS-2. Interaction of insulin to IRS leads 
to phosphorylation of IRS, thus initiating downstream insulin 
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signaling cascades. Binding of insulin to its receptor, receptor 
phosphorylation, tyrosine kinase activity, and phosphorylation 
of IRS are reported in both muscle cells and adipocytes (Kahn 
and Flier, 2000). In addition, the insulin-dependent translocation 
of glucose transporter 4 (GLUT4) in the skeletal muscle and fat 
cells and increased expression of glucose transporter 1 (GLUT1) 
in vascular endothelium cells play a major role in maintaining 
the physiological function of insulin (Stafeev et al., 2017). When 
this physiologic state is perturbed, however, insulin production 
is impaired and leads to reduced insulin secretion and elevated 
blood glucose profile by raising circulating concentrations 
of glucose, free fatty acids, and other nutrients. In most cases, 
such failure is the outcome of direct impairment in the insulin 
signaling pathway, mainly due to a disturbance in the IRS 
and/or downregulation of the insulin-responsive GLUT4 
(Figure 4). These functional defects can have critical metabolic 
consequences in glucose homeostasis and lead to reduced cellular 
responsiveness to insulin action, thereby resulting in a condition 
known as insulin resistance (Eckel et al., 2011).
Insulin resistance is characterized by hyperinsulinemia 
and hyperglycemia, decreased postprandial glucose infusion 
rate, high levels of glycosylated hemoglobin (HbA1c), glucose 
intolerance, hyperlipidemia, elevated plasma inflammatory 
markers, and decreased production of adiponectin (Ye, 2013). 
Insulin resistance is manifested by a decrease in insulin-
stimulated glucose transport and by altered hepatic glucose 
output, mainly via the IRS/PI-3-kinase/PKB signaling arm. 
In response to elevated blood glucose level, pancreatic β-islets 
tend to produce more insulin to overcome the disturbance 
through positive feedback response, favoring a condition 
known as hyperinsulinemia. Hyperinsulinemia is a common 
feature of insulin resistance and T2DM. It is widely accepted 
that obesity-induced metabolic perturbations promote insulin 
resistance and β-cell dysfunction (Eckel et al., 2011). Excess 
abdominal adipose tissue has been shown to release increased 
Fas, which directly affect insulin signaling. In their review, 
Qatanani and Lazar (2007) have described that overweight 
people have impaired ability to uptake circulating glucose 
FIGURE 3 | Endoplasmic reticulum (ER) stress-mediated inflammation. Under ERS condition, the UPR is activated, and this leads to activation of the three principal 
UPR signaling transmembrane receptor proteins including IRE-1, PERK, and ATF6. Activation of the IRE-1 leads to the splicing of the mRNA of a transcription 
factor XBP1 and subsequent expression of sXPB1, a highly active transcription factor for the release of ER-resident enzymes and molecular chaperones. As a 
result, it leads to activation of NF-κB and CHOP resulting in increased expression of proinflammatory gene products. Likewise, activated IRE-1 recruits TRAF2, 
and this complex causes activation of downstream signaling of kinases including JNK and NF-κB, which induce production of inflammatory cytokines and trigger 
inflammation. These inflammatory kinases then phosphorylate and activate downstream mediators of inflammation. Phosphorylation of PERK/eIF2a downstream 
signaling pathway results in uncoupling of NF-κB from IkB. As a result, NF-κB translocates into the nucleus where it activates expression of genes encoding 
proinflammatory cytokines including IL-1, IL-6, and TNF-a, resulting in persistent inflammatory response. On the other hand, autophosphorylation of PERK initiates 
activation of eukaryotic initiation factor 2 (eIF2), which further undergoes phosphorylation resulting in translational attenuation of protein synthesis. Similarly, this 
downstream phosphorylation of eIF2 leads to increased expression of ATF4 and translocation into the nucleus where it binds to the UPRE resulting in transcriptional 
modification of CHOP, a proapoptotic gene transcription factor that initiates inflammation as well as apoptosis. IRE-1 recruits TRAF2 and causes activation of 
downstream signaling of kinases including JNK and NF-κB, inducing the production of inflammatory cytokines. PERK phosphorylates eIF2α, which leads to the 
activation of NF-κB and CHOP to further promote the expression of the inflammatory gene. ERS leads to dissociation of TRAF from TRAF2-procaspase 12 complex, 
which is located on the ER membrane, leading to activation of caspase 12. At the same time, IRE1–JNK complex recruits TRAF2 leading to the formation of the 
IRE1–JNK–TRAF2 complex. The ATF6 pathway also activates NF-κB, further intensifying the expression of inflammatory genes, which secrete more cytokines.
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from the bloodstream into fat and muscle cells and to reduce 
the conversion of glycogen into glucose in the liver, leading to 
elevated blood glucose level.
Several studies have inferred associations between 
hyperglycemia diabetic cardiomyopathy via increased supply 
of free fatty acids (FFAs) to the cardiomyocytes. Johnson et al. 
(2017) hypothesized that chronically elevated blood glucose level 
triggers enhanced transportation of FFAs to cardiomyocytes to a 
concentration that overwhelms the rate of cellular β-oxidation. 
This imbalance may lead to accumulation of triglycerides, 
triggering lipotoxicity and left ventricular dysfunction (Johnson 
et al., 2017). Clearly, the pathophysiology of insulin resistance 
may include many cellular pathways such as the inflammatory, 
neural, and endocrine pathways (Qatanani and Lazar, 2007) and 
deregulation of caloric intake and expenditure in the central 
nervous system, systemic lipid metabolism, and perturbation 
in insulin and glucose signaling in the periphery (Hotamisligil, 
2010). However, the precise molecular mechanisms are subject 
to further research.
ERS-Mediated Insulin Resistance
Disturbance of immune signaling and ER perturbation are 
integrating factors influencing metabolic regulation and 
emergence of metabolic disease. Infiltration of immune cells and 
alterations in inflammatory signaling pathways in adipose tissue 
are characteristic features in obesity-induced insulin resistance. 
Moreover, the ERS and associated perturbation of the immune 
signaling has long been documented as critical factors that cause 
metabolic dysregulation and emergence of metabolic disease 
including insulin resistance and CVD (Hotamisligil, 2010).
Studies have shown that obesity-induced ERS results in 
insulin resistance and T2DM, mainly through activation of the 
JNK terminal, a mediator that leads to an alteration in insulin 
signaling. Several studies have highlighted this phenomenon 
in the pathophysiology of obesity-mediated insulin resistance. 
According to Wellen and Hotamisligil (2005), cells exposed to 
one of the proinflammatory cytokines, such as TNF-α or high 
FFAs, have stimulated inhibition of the serine residues of IRS-
1, thus barring downstream insulin signaling/insulin action. 
FIGURE 4 | ERS-mediated insulin resistance. Following the onset of ERS, the GRP78 BiP dissociates from the three central signaling receptors of the UPR (PERK, 
ATF6, and IRE-1). On the one hand, IRE1–JNK complex recruits TRAF2 leading to the formation of the IRE1–JNK–TRAF2 complex. The IRE1–JNK–TRAF2 complex 
has an effect on ASK1 activation, which may induce JNK phosphorylation, ultimately leading to ablation in insulin receptors and results in insulin resistance. 
Activated IRE-1 recruits TRAF2, and this complex causes activation of downstream signaling of kinases including JNK and NF-κB, which induces production 
of inflammatory cytokines, which trigger inflammation. These inflammatory kinases then phosphorylate and activate downstream mediators of inflammation. 
Consequently, IRE-1-mediated JNK activation disrupts insulin receptor signaling and results in insulin resistance. Phosphorylation of one of these arms, namely, 
the IRE1α, enhances recruitment of TRAF2, which further activates the c-JNK. In turn, c-JNK activation triggers increased production of proinflammatory markers, 
which are believed to alter insulin receptor and leads to insulin resistance. On the other hand, phosphorylation of IRE-1α fosters phosphorylation of IRS-1 through 
JNK-dependent serine and thus inhibits insulin receptor signaling.
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On the other hand, following stimuli such as ERS, elevated 
level of cytokines, and high fatty acids, JNK phosphorylates 
and associates with the IRS-1 and impairs the sensitivity of the 
receptor to insulin action (Figures 2 and 4).
Low-grade chronic inflammation, also known as 
metainflammation, is often triggered in response to an excess 
nutritional state such as high circulating glucose and saturated 
fatty acids and is an emerging mediator of obesity and insulin 
resistance. Commonly, this type of metabolic inflammation is 
triggered via PRR families such as TLRs, inflammasome, RAGE, 
and nucleotide oligomerization domain (NOD) activation. 
TLR2 and TLR4 are highly implicated in obesity-associated 
inflammation, and insulin resistance as activation of these 
receptors leads to elevated production of inflammatory cytokines 
and recruitment of T-cells and macrophages (Ota, 2014).
Studies have shown that excess nutrition/obesity activates the 
immune system, specifically innate immunity through PRRs and 
leads to recruitment of T-cells and macrophages, subsequently 
desensitizing the insulin signaling pathways and leading to 
the development of insulin resistance, a precursor of T2DM 
(Mcfarlane et al., 2001). Adipose tissue macrophages (ATMs) 
are primary sources of proinflammatory cytokines such as 
TNF-α and IL-6, which suppress insulin action and induce the 
development of insulin resistance.
In his seminal article, Hotamisligil has extensively discussed 
the role of JNK, particularly the JNK1 isoform, as a central 
mediator in the pathophysiology of insulin resistance mainly 
by IRS-1 serine phosphorylation and subsequent inhibition of 
insulin actions, through activation of inflammatory signaling 
cascades (Wellen and Hotamisligil, 2005; Hotamisligil and 
Erbay, 2008). IRS-1 and IRS-2 are essential substrates for the 
insulin receptor tyrosine kinases (Chen et al., 2015; Liang 
et al., 2015) in insulin signaling pathways. Thus, ablation 
of the IRS-1/2 receptors by overexpression of inflammatory 
molecules suppresses the insulin signaling pathway and 
results in insulin resistance.
Production of proinflammatory cytokines and suppression 
of IRS-1 has been documented as a primary progressive 
signaling node in the development of insulin resistance. 
JNK activation and downstream activation of inflammatory 
signaling pathways are common features in ERS. Although 
the complete mechanism is yet to be elucidated, under ERS, 
the GRP78/BiP dissociates from the three central signaling 
receptors of the UPR including PERK, ATF6, and IRE-1. 
Phosphorylation of IRE-1α enhances recruitment of TRAF2, 
which further activates the c-JNK (Chen et al., 2015; Liang et al., 
2015). In turn, c-JNK activation triggers increased production 
of pro-inflammatory markers that are believed to alter insulin 
receptor levels and lead to insulin resistance. As illustrated in 
Figure 2, activated IRE-1 recruits TRAF2, and this complex 
causes activation of downstream signaling of kinases including 
JNK and NF-κB, which induces production of inflammatory 
cytokines. Consequently, IRE-1-mediated JNK activation 
disrupts insulin receptor signaling and results in insulin 
resistance. This is in line with data from experimental studies 
conducted on mice wherein significant protection against 
insulin resistance and T2DM following JNK1 gene knockout is 
reported (Hotamisligil and Erbay, 2008). Elevated level of fatty 
acids, high blood glucose, ERS, and mitochondrial dysfunction 
and increased production of inflammatory cytokines result 
in increased inhibitory actions of Ser/Thr phosphorylation of 
IRS-1/2 via activation of JNK, IkB kinase (IKK), mammalian 
target of rapamycin (mTOR) C1/S6K, and MAPK (Boucher 
et al., 2014). ERS leads to suppression of insulin receptor 
signaling, which leads to diminished insulin signaling through 
overactivation of JNK and subsequent serine phosphorylation 
of IRS-1. Mice deficient in XBP1 mRNA develop insulin 
resistance. Upregulation of sXBP-1 mRNA modulates ERS and 
suppresses JNK, which enhances insulin signaling, indicating 
the central role of ERS in insulin resistance and T2DM (Özcan 
et al., 2004).
In studies conducted on heterozygous IKKβ and whole-
body JNK1-deficient mice, moderate protection against high-
diet-induced insulin resistance was observed (Ota, 2014). This 
supports the notion that the IKKβ/NF-κB and JNK pathways 
are involved in the development of insulin resistance and 
are mechanisms that connect inflammation with insulin 
resistance. Besides, activation of the IKKβ/NF-κB pathway 
dephosphorylates IRS-1 through increased expression of 
PTP1B (Kim et al., 2008; Zabolotny et al., 2008). Akt also has 
a central role in regulating insulin action. Akt phosphorylates 
and activates IKK, which leads to activation of NF-κB (Boucher 
et al., 2014), resulting in diminished insulin signaling.
Akt is implicated as a central mediator of various insulin 
actions. Akt mediates insulin actions mainly by regulating 
apoptotic and survival proteins, cell cycle regulating proteins, and 
transcription factors. Among others, Akt phosphorylates murine 
double minute 2 (Mdm2), leading to inhibition of p53-mediated 
apoptosis. The Bax, Bad, and caspase-9 proapoptotic mediators 
are phosphorylated and inhibited by promoting cell survival. It 
also phosphorylates and activates IKK, which leads to activation 
of NF-κB. Endothelial nitric oxide synthase (eNOS) is also 
phosphorylated by Akt, thereby enhancing the production and 
release of nitric oxide (NO), a prominent vasodilator and anti-
inflammatory molecule (Boucher et al., 2014). However, when 
this physiologic balance is perturbed, it may lead to diminished 
insulin signaling, resulting in insulin resistance. However, a 
better understanding of the etiological factors involved and the 
complete molecular mechanisms behind insulin resistance and 
its association with CVD would inevitably be helpful in the effort 
to combat cardiovascular pathologies and T2DM-associated 
comorbidities.
Oxidative Stress and CVD
Oxidative stress is characterized by overproduction and 
accumulation of ROS beyond the antioxidant capacity of living 
cells to scavenge harmful ROS. In living cells, free radicals, 
predominantly in the form of ROS and reactive nitrogen species 
(RNS), are fundamental biochemical components and are 
typical by-products of cellular metabolic processes (Pavithra and 
Vadivukkarasi, 2015). Beyond their physiological roles, however, 
ROS are also the primary etiological factors and characteristic 
features of several chronic diseases including CVD. Interestingly, 
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in the cardiovascular system, ROS acts as messenger in specific 
signaling pathways involved in regulating cardiovascular 
homeostasis (Csányi and Miller, 2014; Cervantes Gracia et al., 
2017). However, the presence of excess ROS deters pathophysiologic 
components in several oxidative stress associated diseases such 
as cardiovascular diseases (CVD), rheumatoid arthritis, cancers, 
ulcerative colitis, and neurodegenerative disorders (Pavithra and 
Vadivukkarasi, 2015).
Several studies have elucidated the effects of ROS-induced 
oxidative stress in CVD and further demonstrated ROS as a 
significant contributing factor in the pathogenesis of CVD. 
Accumulating evidence indicates a crosstalk between ROS 
generation and the ERS-initiated UPR activation. Indeed, 
studies have shown that although most of the ROS in the ER is 
generated via Ero1, such redox imbalance can also be triggered 
by altered PERK and ATF4,functions which induce genes that 
facilitate elimination of ROS (Görlach et al., 2006). Furthermore, 
the effects of over-accumulation of ROS not only are confined to 
inducing oxidative stress in cardiomyocytes but also impair the 
antioxidant system (Liu et al., 2013), which serves as a defense 
system against free radicals. A thorough understanding of ROS 
in the pathophysiology of CVD could lead to new antioxidant-
associated therapies.
Under normal physiological balance, damaging effects of 
free radicals are reversed by enzymatic antioxidants including 
superoxide dismutase (SOD), glutathione peroxidase (GPx) and 
catalase, and non-enzymatic antioxidants such as β-carotene, 
bilirubin, vitamin E, and vitamin C (He and Zuo, 2015). 
However, when this naïve protective system is perturbed, an 
excess of free radicals accumulates, overriding the antioxidant 
system and threatening the scavenging efficiency of existing 
antioxidants, thus resulting in a condition known as oxidative 
stress. Such alterations affect crucial cellular events such 
as immune cell differentiation, nervous system physiology 
regulation, stem cell differentiation, guanylate cyclase 
activation, and phosphatases, kinases, and growth factor 
signaling pathways (Cervantes Gracia et al., 2017).
Several studies have elucidated the effects of ROS-induced 
oxidative stress in CVD and emonstrated ROS as a significant 
contributing factor in the pathogenesis of CVD. Although ROS 
are well known as critical players in cardiometabolic disorders, 
the exact mechanisms of how ROS lead to the development 
of CVD is not clearly understood. Nevertheless, emerging 
studies have shown the role of ROS in the pathogenesis of 
different subtypes of CVDs including congestive heart failure, 
arteriosclerosis, ischemic heart disease, and xenobiotics-
mediated cardiomyopathies via apoptosis (Ilavenil et al., 
2015). Furthermore, the presence of excess ROS has oxidation-
mediated damaging effects on cellular macromolecules such as 
lipids, cell membrane, proteins, and DNA, which alter cellular 
function and may contribute to the development of CVD and 
diabetes (Rajeshwari and Raja, 2015). Of more interest, studies 
have shown that in conditions of oxidative stress, nuclear 
E2-related factor-2 (Nrf2) transcription factor is translocated 
into the nucleus and binds to the antioxidant response element 
(ARE) through which the gene expressions of enzymatic 
antioxidant systems including heme oxygenase-1 (HO-1) and 
other enzymes involved in glutathione metabolism is regulated 
(He and Zuo, 2015). Thus, given the fact that apoptosis is a 
major causative factor for various cardiovascular pathologies, 
correlating apoptosis induced by ROS and ERS might work as 
a new perspective approach to elucidate intersecting factors for 
these two etiologies.
CARDIOVASCULAR THERAPEUTICS
Pharmaceutical Potentials of 
Phytochemicals in CVD
Plants are the basis of ethnomedicines and have been used 
as sources of pharmaceuticals for various ailments for 
centuries and plants, and their derivatives have remained 
primary sources for lead compounds for the discovery and 
development of new therapeutics for several infectious and 
noninfectious diseases (Odey et al., 2012). Existing reports 
indicate that nearly 50% of all therapeutic drugs introduced by 
pharmaceutical industry are in some ways made from plant-
based active lead compounds (de Oliveira et al., 2008). Since 
medicinal plants are abundant sources of phytochemicals that 
have wide ranges of pharmaceutical properties, the research 
interest and focus on plant-based bioactive compounds to 
search for novel medicinal agents and develop potential 
therapeutics for various ailments will increase dramatically in 
the coming decades.
Phytochemicals are bioactive compounds found naturally in 
plants and their products including vegetables, fruits, medicinal 
plants, and aromatics; and these plant chemicals are located in 
different anatomical parts of plants, namely, the leaves, fruits, 
flowers, and roots (Vasanthi et al., 2012). Phytochemicals are 
classified as primary and secondary metabolites. While the 
former serves as a primary source of energy and has roles in 
maintaining proper growth and development of plants, the 
latter play a role in plant metabolism and defense system against 
pathogens. Phytochemicals comprise a range of chemical groups 
including polyphenols, alkaloids, flavonoids, terpenoids, sterols, 
and vitamins, each having unique characteristics and bioactivity. 
Owing to their abundant phytochemical constituents, less 
adverse effects, and relative cost-effectiveness, plant-derived 
phytochemicals have been preferred over synthetic drugs 
(Vuddanda et al., 2010; Azwanida, 2015).
Several compounds with various potential pharmacological 
activities on different types of CVDs and their risk factors, 
including antioxidant, anti-angiogenic, anti-ischemic, anti-platelet 
aggregation, anti-inflammatory, anti-hypercholesterolemia, 
immunosuppressant, and anti-thrombotic activities, have been 
identified (Bradamante et al., 2004; Das and Das, 2007; Pagliaro 
et al., 2015). However, the underlying biomolecular mechanisms 
of many of these phytochemical compounds are still incomplete 
to substantiate their novelty and functionality. In this sense, 
besides the efforts and rising interests in plant-based bioactive 
compounds for the discovery of therapeutics for CVDs, it is 
also critically important to give emphasis to unfold useful 
information on the biological, toxicological, and structure–
activity relationships. One way to achieve this is through 
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employing a multidisciplinary systematic approach involving in 
vitro, in vivo, in silico, and molecular approaches to gain more 
vigorous pharmacological information.
Recent studies have revealed the role of epigenetic alterations 
including DNA methylation and histone modification in 
the progression of CVDs. Interestingly, various plant-based 
bioactive compounds are shown to reverse and ameliorate such 
epigenetic alterations. Resveratrol and curcumin (Table 1) are 
among such compounds that have been identified as potential 
phytochemicals that can modulate altered epigenetic signaling 
pathways (Schiano et al., 2015; Vietri et al., 2015). While 
resveratrol modulates CVS-related disorders through inhibition 
of phospholipase A2 and cyclooxygenase-2 (COX-2) activities 
and antagonizing NF-κB, TNF-α, IL-6, inducible nitric oxide 
synthase (iNOS), and monocyte chemoattractant protein-1 
(MCP-1) (Pagliaro et al., 2015), curcumin modulates CVDs 
through inhibition of prostaglandin production and NF-κB 
activity, GRP94 induction, and modulation of the Akt/Nrf2, ERK, 
MAPK, p38, and JNK signaling molecules (Kapakos et al., 2012; 
Zhang et al., 2015; Zhang et al., 2017b). Abscisic acid (Table 1) 
has been investigated for its antidiabetes activity in obesity-
related inflammation via peroxisome proliferator-activated 
receptor (PPARγ)/NF-κB signaling pathway. Carotenoids 
(Table 1) have been shown to modulate obesity-associated 
inflammation, atherosclerosis, and CVD through ameliorating 
the IGF-1, IL-1β, IL-6, and MCP-1 signals (Beukes et al., 2014). 
There are many more phytochemicals that have been proven to 
modulate risks of cardiovascular dysfunction and protect the 
cardiac system. Given the novelty of some of UPR-associated 
molecular targets, it is critically essential to emphasize the use 
of phytochemicals as sources of potential bioactive compounds 
to modulate CVDs resulting from compromised ER, epigenetics 
mechanisms, environmental factors, or other traditional factors. 
Some of the best studied phytochemicals in this context, their 
rich sources, their biological activities, the mechanisms of 
action (MOA), and associated molecular targets are described 
in Table 1.
UPR as a Potential Therapeutic Target 
in CVDs
The ERS and subsequent activation of the UPR have been 
implicated in the pathogenesis of a number of CVDs including 
atherosclerosis, heart failure, and ischemic heart disease 
(Glembotski, 2014). Targeting the UPR signaling pathway may 
be a potential path to modulate different types of CVDs using 
pharmacological interventions and to mitigate ERS-associated 
heart diseases.
Therapeutic Approaches/Strategies 
in UPR-Mediated CVDs
There are two approaches to manipulate ERS-activated UPR 
or utilize the UPR components as therapeutic targets for the 
treatment of CVDs. These include activating selective mediators 
of the UPR adaptive system and deactivating the ERS-initiated 
proapoptotic pathway (Minamino et al., 2010). Pharmacological 
intervention of modulating UPR signaling components can 
potentially stimulate an increased capacity to alleviate protein 
misfolding, with positive therapeutic effects in cardiac and 
related metabolic diseases.
Other strategies to utilize the UPR as a target for 
cardiovascular therapy may include decreasing misfolded/
unfolded proteins, intervening in the activation of the UPR 
sensors. In particular, selectively inhibiting the dissociation of 
GRP78 from the three ERS detectors or inhibiting the activated 
UPR sensors and other effectors of the UPR signaling may 
have efficient therapeutic potential (Liu and Dudley, 2014). 
While a decrease in misfolded/unfolded proteins reduces 
the burden caused due to abnormally deposited unfolded 
proteins within the lumen of ER and, as a result, leads to 
elimination of misfolded proteins, inhibition or attenuation 
of the UPR sensors or their downstream proximal or distal 
effectors including eIF2a/ATF4, ATF6N, and XBP1 with 
selective inhibitor molecules could also be a potent approach 
to mitigate the chronic effects of UPR activation. As illustrated 
in Table 3, apelin-13 is reported to have protective effects 
against ischemia/reperfusion (I/R) injury through inhibition 
of ERS-mediated apoptosis and the PERK/CHOP canonical 
UPR signaling pathway (Chen et al., 2015).
Increased expression of chaperone protein GRP78 is central 
to the recognition of unfolded/misfolded proteins and the 
coordinated activation of the UPR signaling (Toth et al., 2007). 
At steady state, GRP78 remains bound to the luminal domain of 
the three ERS sensors. However, due to its high affinity towards 
misfolded/unfolded proteins, GRP78 dissociates from the three 
sensors and binds to unfolded/misfolded proteins when ERS is 
induced. Clearly, targeting GRP78, which is a determinant in 
the initiation and progression of ERS-initiated UPR signaling 
process, could be a useful therapeutic approach in CVDs.
Several phytochemicals and small molecules have been 
investigated and identified for their modulating effect against 
GRP78 and downstream signaling. Bisoprolol (Tables 2 
and 3), for example, has been reported to attenuate the UPR 
signaling pathway through suppression of TNF-α and IL-6 
secretion, which consequently downregulates the PERK/
ATF4/eIF2α signaling in myocardial I/R injury (Zhang et al., 
2017b). Likewise, notoginsenoside R1 (Table 2) is indicated 
to suppress GRP78, phosphorylated PERK, ATF6, IRE1, 
CHOP, and phosphorylated JNK (Chen et al., 2015). There 
are several other compounds that have been discovered 
for their potential in mediating the GRP78 downstream 
pathways in cardiovascular-related pathologies. For example, 
Salubrinal93 (Table 2) prevents cardiac hypertrophy, one of 
the underlying pathophysiologies of cardiac dysfunction and 
hypertension, a prominent risk factor of cardiac pathologies, 
through dephosphorylation of eIF2α (Minamino et al., 2010). 
Metoprolol and propranolol (Tables 1 and 3), β-adrenergic 
receptor (β-AR) blockers, were also tested and modulated 
heart failure caused by cardiac hypertrophy in rats. Metoprolol 
and propranolol exerted this effect via downregulation of 
GRP78, XBP-1, calmodulin kinase II (CaMKII), and CHOP 
leading to alleviation of ERS and ERS-induced apoptosis 
(Chen et al., 2015).
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TABLE 1 | Plant-based CVD therapeutics, their pharmacological activities, mode of actions, and molecular targets.
Compound/class 
of phytochemical
Natural sources Pharmacological activities Mechanism of action 
(MOA)
Molecular targets References
Resveratrol/
polyphenolic 
compound
Polygonum 
cuspidatum, grapes, 
peanuts, and berries
• Inhibition of lipid 
peroxidation
• Free radical scavenging
• Inhibition of platelet 
aggregation
• Anti-inflammatory activity
• Vasorelaxation activity
• Modulation of lipid 
metabolism
• Increases the expression of 
NO synthase
• Decreases the expression 
of vasoconstrictor ET
• Inhibits stress-induced ET-1 
gene expression
• Alteration of eicosanoid 
synthesis
• Attenuation of arachidonic 
acid and prostaglandin E2 
synthesis
• Inhibition of phospholipase 
A2 and COX-2 activities
• Antagonizes NF-κB, TNF-α, 
IL-6, iNOS, MCP-1
AMPK, SIRT-1 pathway,
NF-κB, TNF-α, IL-6, 
iNOS,
MCP-1
(Bradamante et al., 
2004; Das and Das, 
2007; Pagliaro et al., 
2015)
Carotenoids Rosa arvensis, Bibes 
nigrum, Fagus sylvatica, 
Malus domestica
Obesity-associated 
inflammation, 
atherosclerosis, 
cardiovascular disease
…………………… IGF-1, IL-1β, IL-6, 
MCP-1
(Beukes et al., 2014)
Brassica oleracea Broccoli, cauliflowers, 
Brussel sprouts, and 
kale
• Antioxidant
• Anti-inflammatory
• Antithrombotic effects.
………………………… Nrf2, MAPK, JNK, Akt, 
PKB, AMPK, SIRT-1, 
PPARα, UCP2
(Pagliaro et al., 2015)
Naringenin/
flavonoids
Grapefruit and orange • Antioxidant activity
• Protects LDL oxidation
• Increases the activity of 
antioxidant enzymes and 
non-enzymatic antioxidants
• Inhibits generation of free 
radicals
LOX and COX pathways (Vasanthi et al., 2012)
Curcumin/phenolic 
compound
Turmeric (Curcuma 
longa)
• Anti-inflammatory, 
antiplatelet, antioxidant 
activity
• Inhibition of prostaglandin 
production and NF-κB 
activity, an increase of 
cytokine production
• GRP94 induction
JAK2/STAT3, AMPK/
UCP2, Akt/Nrf2, ERK, 
MAPK p38, JNK, ICAM-
1, MCP-1, and IL-8
(Kapakos et al., 
2012; Zhang et al., 
2015)
Isoflavones/
polyphenols
Soybeans, fruits, 
vegetables, legumes, 
herbs, spices, stems, 
flowers
• Free radical scavenging 
and antioxidant activity
• Anti-inflammatory activity
• Inhibition of eicosanoid 
generating enzymes
• Modulation of the 
production of pro-
inflammatory cytokines
ERs, Nrf1, iNO, COX-2, 
TNF-α, ICAM-1, VCAM-
1, E-selectin, MCP-1, 
ERE, CVD ion channels, 
inhibiting calcium 
channels or activating 
potassium channels
(García-Lafuente 
et al., 2009)
(Scholz et al., 2010)
Catechin Green tea, apples, 
cocoa, and berries
• Antioxidant, anti-
hypertensive, 
anti-inflammatory, 
anti-proliferative, 
anti-thrombogenic, 
hypocholesterolemia effects
• Upregulation of 
proinflammatory molecules 
by suppression of NF-κB 
activity
• Modulation of cholesterol 
metabolism
(Vasanthi et al., 
2012)
Quercetin/
flavonoid
Onions, apples, and 
tea/
• Anti-thrombogenic
• Antioxidant
• Anti-platelet aggregation
• Decreases superoxide 
production
• Inhibition of phospholipase 
A2 activity
• Inhibition of MAP kinase 
activation
• Decreases platelet 
aggregation and increases 
platelet-derived nitric oxide 
release
• Inhibition of phospholipase 
A2 activity
• Blockage of the LOX and 
COX pathways
LOX and COX 
pathways, NF-κB gene
(Vasanthi et al., 
2012)
Geraniol Citrus spp. • Improve insulin resistance, 
suppresses HMG-
CoA) reductase activity, 
hepatoma, melanoma, and 
leukemia cells
…………………… PPARγ (Beukes et al., 2014)
(Continued)
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Apoptosis of cardiomyocytes has been reported in various 
diseases of the cardiovascular system including myocardial 
ischemia, heart failure, atherosclerosis, and Diabetic 
cardiomyopathy (DCMP) (Lee and Gustafsson, 2009). PUMA 
has recently been identified as a critical proapoptotic pathway 
mediator and important contributor in the pathophysiology 
of CVDs including I/R injury. p53-up-regulated modulator 
of apoptosis (PUMA) is a critical contributor in ERS-induced 
apoptosis in cardiomyocytes, a novel proapoptotic effector 
upstream of Bax/Bak, and sequesters the prosurvival Bcl-2 family. 
This makes it an appealing therapeutic target for pharmacological 
intervention to attenuate myocyte apoptosis in CVD. In light of 
this, a study has demonstrated that ERS elicited by thapsigargin 
or tunicamycin led to upregulation of PUMA in cultured cardiac 
myocytes. Importantly, following PUMA-targeted suppression 
using small molecule shRNA, the cardiomyocytes managed to 
recover from ERS-induced cell death; ablation of PUMA has also 
reduced heart infarct size and attenuated apoptosis in I/R injury 
(Toth et al., 2007). Trigonelline (Table  2) is another candidate 
compound that is identified as having antiapoptotic effect 
against H2O2 induced necrosis and apoptosis in cardiomyocytes 
via inhibition of proapoptotic caspases and upregulation of the 
distal antiapoptotic Bcl-2 (Ilavenil et al., 2015). However, besides 
their antiapoptotic activity, there is a concern over some of these 
caspase inhibitors, as some have been reported to induce cell 
necrosis (Ni et al., 2016). Thus, caution is needed in targeting 
selected ERS markers to minimize deleterious effects.
Studies have shown that CHOP mediates the transcriptional 
repression and activation of proteins from Bcl-2 family 
(Minamino and Kitakaze, 2010). Suppression of the prosurvival 
protein Bcl-2 by CHOP may be a possible mechanism in CHOP-
induced cellular apoptosis (Li et al., 2014). Hence, targeting 
this proapoptotic protein could be envisioned as a potential 
strategy for pharmacological intervention. Metformin is well 
studied for its cardioprotective effects in both cardiomyocytes 
and rodents. As described in Tables 2 and 3, metformin exerts 
cardioprotective effects through several mechanisms including 
selective activation of PERK-ATF4 UPR arm, and upregulation 
of CHOP mRNA and protein (Quentin et al., 2012). Berberine 
is a natural compound with potent modulatory effects in CVS 
pathologies. Berberine modulates myocardial I/R injury in rats 
and cell line models through activation of AK2/STAT3 and 
JAK2/STAT3 signaling pathways, attenuation of ERS-induced 
apoptosis, downregulation of the phosphorylation levels of 
myocardial PERK and eIF2α, and expression of ATF4 and CHOP 
(Zhao et al., 2016) (Tables 2 and 3).
The IRE1-α-dependent apoptotic signaling occurs via diverse 
pathways. Among others, the IRE1-α interacts with the adaptor 
protein TRAF2. IRE1α and TRAF2 interact with a mitogen-
activated protein kinase ASK1, which subsequently phosphorylates 
JNK. Indeed, this pathway is one of the main pathways that trigger 
myocyte apoptosis, which may lead to various cardiovascular 
pathologies and chronic inflammation. Perhaps strategies to 
inhibit the IRE1-α/TRAF2 interaction, which would likely 
TABLE 1 | Continued
Compound/class 
of phytochemical
Natural sources Pharmacological activities Mechanism of action 
(MOA)
Molecular targets References
Berberine/alkaloid Hydrastis canadensis • Anti-oxidant, 
anti-inflammatory
• Antihyperlipidemic activity
• Antihypertensive activity
• Upregulation of SOD and 
UCP2
• Downregulation of NADPH 
oxidase expression
• Attenuation of ER stress-
induced apoptosis
• Activation of the Nrf2 
pathway
JAK2/STAT3 signaling 
pathway, UPR signaling 
pathway, Nrf2 pathway, 
AK2/STAT3 signaling 
pathway, C-AMPK and 
MAPK/ERK pathway, 
NF-κB signaling 
pathway
(Vuddanda et al., 
2010; Pagliaro et al., 
2015)
Abscisic acid Rosa arvensis, 
Ribes nigrum, Fagus 
sylvatica, Malus 
domestica
• Diabetes, obesity-related 
inflammation
…………………… PPARγ, NF-κB (Beukes et al., 2014)
Sulforaphane Broccoli, cauliflowers, 
Brussel sprouts, and 
kale
• Antioxidant activities
• Anti-inflammatory activities
• Inhibition of angiogenesis
• Inhibition of phase I 
enzymes and DNA adducts
• Induction of phase II 
antioxidant detoxifying 
enzyme,
• Induction of cell cycle arrest
• Expression of Nrf2
• Nrf2-dependent phase 2 
enzymes activation
• Expression of detoxification 
enzymes antioxidant 
response elements (AREs)
• Reduction of VCAM-1 
synthesis
VCAM-1, Nrf2, ARE (Pagliaro et al., 2015)
UCP2, uncoupling protein 2.
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block the proapoptotic Ask1/JNK branch, could also be a viable 
therapeutic approach. Rapamycin is another compound with the 
potential of modulating ERS-initiated UPR activation. One way 
through which this compound ameliorates ER stress-induced 
pathologies such as insulin resistance, apoptosis, and adipocyte 
dysfunction, which are implicated in cardiac dysfunction, is 
through inhibition of mTOR (Table 2) (Jung and Choi 2016). In 
addition, rapamycin suppresses IRE-1–JNK signaling pathway, 
which leads to chronic inflammation and altered insulin signaling. 
Other studies have also demonstrated the potential of caspase 
inhibitors in modulating apoptosis. For example, bisoprolol is 
implicated in myocardial I/R injury through downregulation of 
caspase-12 and caspase-3, leading to downregulation of the PERK/
ATF4/eIF2α UPR signaling pathway (Zhang et al., 2017b).
In general, inhibition of UPR signaling seems a promising 
direction in the discovery of novel therapeutics for CVDs. Many 
encouraging preclinical studies (in vitro and in vivo) have been 
conducted, but gaps and limitations remain in understanding 
many underpinning scenarios. For example, it is clearly 
understood that under normal circumstances, activation of the 
UPR has a protective or adaptive role, but chronic activation will 
have deleterious effects. Unlike acute interventions, which could 
be undertaken with acceptable risks of side effects, Kim et al. 
(2008) have discussed in their review that prolonged perturbation 
of the ERS-initiated UPR signaling in a broad systemic manner 
could potentially have indiscriminate deleterious effects on some 
tissues and organs. This necessitates the need for a critical time 
point and temporary therapeutic strategies in targeting the UPR 
for therapeutic intervention. Perhaps a specific approach to assess 
which of the three ERS signaling arms and associated mediators 
are activated in response to ERS-inducing stimuli would be very 
helpful to develop a better strategy for UPR targeted therapeutics. 
TABLE 2 | Preclinical therapeutics (natural compounds, small molecules, or peptides) targeting the UPR signaling pathway (in vitro).
Compound Experimental model Disease model Therapeutic activity/target Indication References
Berberine H9c2 cardiomyocyte Myocardial ischemia/
reperfusion (MI/R) injury
Activation of AK2/STAT3 
signaling pathway and JAK2/
STAT3 signaling pathway, 
attenuation of ERS-induced 
apoptosis
Downregulation of the 
phosphorylation levels 
of myocardial PERK 
and eIF2α, expression 
of ATF4 and CHOP in 
heart tissues
(Zhao et al., 2016)
Bisoprolol H9c2 cardiomyocyte Myocardial ischemia/
reperfusion (I/R) injury
Inhibition of UPR signaling 
pathways, suppression of 
TNF-α and IL-6 secretion, 
downregulation of caspase-12 
and caspase-3 expressions
Attenuation of UPR 
signaling pathway, 
downregulation of 
PERK/ATF4/eIF2α
(Zhang et al., 2017b)
AG1478 and 542 
(small-molecule EGFR 
inhibitors)
H9c2 cardiomyocyte Hyperlipidemia/obesity-
induced cardiac injuries
Downregulation of TLR4/c-
Src, suppression of TNFα and 
IL-6 expression
Reduction of cardiac 
inflammatory injuries 
and apoptosis
(Li et al., 2016)
Adiponectin U0126 
(ERK1/2 inhibitor)
H9c2 cardiomyocyte Palmitate-induced 
apoptosis, 
lipotoxicity-induced 
cardiomyopathy
Caspase-3 and PARP activity 
inhibition, ERK1/2 signaling 
pathway, inhibition of the Akt 
signaling pathway
Increase the protein 
level of PI3K/Akt and 
decrease the protein 
level of ERK1/2
(Wei et al., 2012)
Trigonelline H9c2 cardiomyocyte H2O2-induced H9c2 
cell deaths, oxidative 
stress-mediated CVD
Downregulation of 
proapoptotic caspase-3 and 
caspase-9, upregulation of 
Bcl-2 and Bcl-XL expression
H2O2 induced necrosis 
and apoptosis
(Ilavenil et al., 2015)
Elatoside C H9c2 cardiomyocytes ————– Upregulation of p-STAT3 and 
downregulation of CHOP, 
GRP78, JNK
Suppression of ER 
stress
(Liu, H. et al., 2016)
D942 (small molecule) 
and curcumin 
(combination treatment)
Primary cardiomyocyte Myocardial ischemia/
reperfusion (I/R) injury
Activating AMPK pathway or 
inhibiting mTOR signaling
Upregulates autophagy 
and promotes cell 
survival
(Yang et al., 2013)
Metformin Primary rat 
cardiomyocytes
N/A Selective activation of PERK-
ATF4 UPR arm, Upregulation 
of CHOP mRNA and protein
Cardioprotective effect (Quentin et al., 2012)
Rapamycin L6 myotubes Diabetic 
cardiomyopathy (DCM)
Inhibition of mTOR (mammalian 
target of rapamycin), selective 
suppression of the IRE1–JNK 
signaling pathway, restoration 
of hyperlipidemia-induced 
ER stress/NF-κB-mediated 
pathway
Ameliorates ER 
stress-induced insulin 
resistance attenuated 
ER stress-induced 
apoptosis, ameliorates 
adipocyte dysfunction, 
upregulates autophagy
(Jung and Choi, 2016)
Notoginsenoside R1 H9c2 cardiomyocytes ————— Suppression of GRP78, 
p-PERK, ATF6, IRE1, CHOP, 
p-JNK
—————– (Liu, M. Q. et al., 2016)
Salubrinal93 Cardiac hypertrophy 
and hypertension
Prevention of eIF2a 
dephosphorylation
(Minamino et al., 2010)
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According to Ni et al. (2016) TNF-α targeted inhibition of 
caspases using inhibitor molecule, ZVAD-fmk, has shown an 
inhibitory effect against apoptosis at early intervention but 
promoted cell necrosis in prolonged treatment (Ni et al., 2016). 
This effect has been observed in both in vitro and in vivo models, 
raising concern over the safety of emerging caspase inhibitors, 
which are undergoing clinical trials. As such, caution is needed in 
targeting selected ERS markers to minimize deleterious effects. 
This necessitates the need for further investigation to elucidate 
how and when cells decide to enter necrotic or apoptotic pathways 
as well as the cross-talk between different cell death mechanisms.
Therapeutics Under Clinical Trials Targeting ERS 
and UPR
The past decade has seen fast developments in therapeutic 
approaches to treat various metabolic disorders including 
high-lipid-induced insulin resistance and T2DM. Some of the 
potential agents targeting ER pathway could possibly evolve 
as effective strategies for obesity-associated complications. 
Tauroursodeoxycholic acid (TUDCA) and sodium phenylbutyrate 
(PBA) (Table 4) are some of the drugs that have been investigated 
for their therapeutic effects in obese people who have high-lipid-
associated insulin resistance. The pharmacological effects and the 
mechanism of action (MOA) of these drugs have been linked to a 
decrease in ERS (NCT00771901 and NCT02344186). According 
to the investigation, TUDCA and PBA modulate obesity-related 
insulin resistance by reverting ERS and associated biomarkers, 
thus improving insulin action (NCT00771901). Liraglutide 
(Table 4) is another pharmacological drug that was found to 
ameliorate ER stress and adipose tissue in obese people who 
have T2DM (NCT02344186). Alpha-lipoic acid (ALA) (Table 4) 
is a natural compound that is a potent antioxidant and free 
radical scavenger with attractive pharmacological activity for 
the treatment of T2DM. This compound has undergone phase 
4 clinical trials, and its pharmacological effects have been linked 
to modulation of the insulin signal pathways and antagonizing 
TABLE 3 | Preclinical therapeutics (natural compounds, small molecules, or peptides) targeting the UPR signaling pathway (in vivo).
Compound Experimental 
model
Target disease Therapeutic activity/target Indication References
Berberine Male Sprague–
Dawley rats
Myocardial ischemia/
reperfusion (I/R) injury
Activation of AK2/STAT3 
signaling pathway and JAK2/
STAT3 signaling pathway, 
attenuation of ERS-induced 
apoptosis
Downregulation of the 
phosphorylation levels 
of myocardial PERK 
and eIF2α, expression 
of ATF4 and CHOP in 
heart tissues
(Zhao et al., 2016)
Bisoprolol Sprague–Dawley 
rats
Myocardial ischemia/
reperfusion (I/R) injury
Inhibition of UPR signaling 
pathways, suppression of 
TNF-α and IL-6 secretion, 
downregulation of caspase-12 
and caspase-3 expressions
Attenuation of UPR 
signaling pathway, 
downregulation of 
PERK/ATF4/eIF2α
(Zhang et al., 2017b)
AG1478 and 542 (small-
molecule EGFR inhibitors)
C57BL/6 mice Hyperlipidemia/obesity-
induced cardiac injuries
Downregulation of TLR4/c-Src, 
suppression of TNFα and IL-6 
expression
Reduction of cardiac 
inflammatory injuries
(Li et al., 2016)
Adiponectin U0126 
(ERK1/2 inhibitor)
Lipotoxicity-induced 
cardiomyopathy
Inhibition of the caspase-3 
and PARP activity, inhibition 
of ERK1/2 signaling pathway, 
activation of the Akt signaling 
pathway
Increase protein 
level of PI3K/Akt and 
decrease the protein 
level of ERK1/2
(Wei et al., 2012)
Thioredoxin 2 Wistar rats Diabetic 
cardiomyopathy
Diminish high-glucose-induced 
mitochondrial oxidative damage 
and improved ATP production
(Li et al., 2017)
D942 (small molecule) and 
curcumin (combination 
treatment)
C57BL/6 mice Myocardial ischemia/
reperfusion (I/R) injury
Activation of AMPK pathway or 
inhibition of mTOR signaling
Upregulates autophagy 
and promotes cell 
survival
(Yang et al., 2013)
Tauroursodeoxycholic acid 
(chemical chaperone)
Calreticulin-
induced 
Transgenic mice 
hearts (Heart CRT+)
Heart failure Inhibition of IRE1α pathway of 
the UPR
Prevents cardiac 
fibrosis and preserve 
heart function
(Groenendyk et al., 
2016)
Metformin (AMPK activator) Diabetic obese 
mice
Cardiomyopathy Activation of AMPK-induced 
PPARδ
Suppresses ER stress 
and protects endothelial 
function
(Jung and Choi, 2016)
Apelin-13 —————— Myocardial ischemia/
reperfusion (I/R) injury
Modulation of PERK/CHOP, 
PI3K/Akt, AMPK and ERK 
pathways
Inhibits ERS-dependent 
apoptosis activation 
via the
(Lee and Ozcan, 
2014)
Atorvastatin —————— Heart failure GRP78, caspase-12, CHOP Inhibits ER stress-
induced apoptosis
(Liu, M. Q. et al., 
2016)
Metoprolol and propranolol 
β-adrenergic receptor 
(β-AR) blockers
Rats Hypertrophic failing 
hearts
Downregulation of GRP78, 
XBP-1, and calmodulin kinase II 
(CaMKII), CHOP
Suppression of ERS 
and ERS-mediated 
apoptosis
(Liu, M. Q. et al., 
2016)
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the oxidative and inflammatory stresses (NCT01056497). 
All these findings implicate the significance of targeting ERS 
and associated pathways for pharmacological intervention 
of common metabolic disorders including insulin resistance, 
T2DM, and CVD.
Challenges and Future Perspectives
As discussed earlier, ERS and associated cellular events, mainly 
ERS-induced myocyte apoptosis, have been implicated in the 
initiation and progression of different types of CVDs. In line 
with this, alleviation of ERS and its constituents has recently 
emerged as a potential therapeutic target to intervene in CVDs 
such as heart failure, hypertension, and atherosclerosis (Zhang 
et al., 2017b). Given that myocyte apoptosis is one of the major 
contributors to CVDs, perhaps pathways involved in this event 
offer an attractive therapeutic target to combat the diseases. 
In their review, Toth et al. highlighted that the ERS pathway 
and mediating molecules that govern cell survival and cell 
death are the best targets for pharmacological intervention. 
However, there are multiple downstream pathways that lead to 
proapoptotic events in ERS; as a result, therapeutic strategies 
targeting or modulating a single apoptotic pathway may not 
be enough to preserve the survival of cardiomyocytes (Xu 
et al., 2005; Kim et al., 2008). A deep understanding of the 
interconnecting pathways involved in ER-initiated cell death is 
essential to fully validate targets for drug discovery.
Most of the components of UPR signaling, including the 
proapoptotic pathway, are widely expressed; thus, blocking 
their activity may trigger unpredictable adverse effects. This is 
particularly true in conditions where delivery of the ligand to 
the target cell types or tissue fails. Hence, further research in 
ERS is needed to elucidate the best therapeutic targets within 
the various interconnecting networks. Moreover, molecular 
mechanisms of ERS-linked proteins and genes regulation 
involved in the initiation and progression of ERS-induced cell 
death are essential for identification of novel molecular markers 
for future drug discovery.
CONCLUDING REMARKS
CVDs constitute a major challenge and are at an epidemic 
proportion worldwide. Despite significant progress made 
thus far, the development of novel and effective therapeutics 
for CVDs has continued to be a major research goal due to 
limitations and reported side effects in existing therapies. The 
impact of ERS-induced activation of UPR signaling in the 
pathophysiology of CVDs is well documented in numerous in 
vitro and animal studies. The apoptotic event that is triggered 
following chronic ERS has been implicated in the development 
and progression of CVDs. Nevertheless, further research is 
warranted to identify the best drug targets within the ERS 
pathway to expedite the fight against cardiovascular and other 
metabolic diseases.
ERS pathways may offer attractive targets to combat 
cardiovascular pathologies and discover therapeutic alternatives 
in disease processes. However, there are still many constraints 
in terms of understanding the molecular mechanisms of 
this phenomenon. As such, understanding the underlying 
molecular mechanisms of events including the stress-associated 
UPR activation and ERS-induced apoptosis resulting from 
protracted ERS is of paramount importance. This will lead to 
gain of substantial biomolecular information, which will help 
in identifying novel targets for the discovery of new therapeutic 
approaches and the development of effective drugs. Therefore, a 
better and improved understanding of the molecular mechanisms 
underpinning activation of UPR and the ensuing cellular 
apoptosis in CVD will provide us with new and novel biological 
targets that can be utilized for potential therapeutic interventions 
and drug discovery for CVDs.
Meanwhile, owing to their immense health benefits, fewer 
side effects, and a broad spectrum of pharmacological potentials 
against different ailments, phytochemicals have become the 
primary focus in the discovery and development of therapeutics 
for a range of diseases including CVD. As described in Tables 
1, 2, and 3, several promising compounds that modulate CVDs 
and protect CVS by interfering with ERS and UPR signaling 
and associated mediator molecules have been identified. 
Thus, given the significant role of phytochemicals as potential 
bioactive compounds to modulate CVDs resulting from 
compromises in epigenetics mechanisms or other traditional 
risk factors, it is a better alternative and perhaps a promising 
avenue to emphasize the research on such and other bioactive 
compounds with multidisciplinary approaches to foster the 
ongoing efforts to develop novel drugs and better therapeutic 
approaches for CVDs.
TABLE 4 | Clinical trials of therapeutics targeting ERS and UPR.
Compound Disease Targeted mechanisms Clinical trial phase Reference
Tauroursodeoxycholic acid (TUDCA) Insulin resistance ERS N/A NCT00771901
Sodium phenylbutyrate (PBA) Insulin resistance ERS N/A NCT00771901
Liraglutide Type 2 diabetes ERS Phase 4 NCT02344186
Buphenyl Diabetes
Insulin resistance
ERS Phase 4 NCT00533559
Alpha-lipoic acid (ALA) Type 2 diabetes
Prediabetes
ERS Phase-4 NCT01056497
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